Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
about
A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyDiverse mechanisms of antiepileptic drugs in the development pipelineUpdate on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyPharmacological Approaches for Treatment-resistant Bipolar DisorderRecent treatment advances and novel therapeutic approaches in epilepsySynthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent.Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.Update on treatment of partial onset epilepsy: role of eslicarbazepineEfficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Eslicarbazepine acetate (BIA 2-093).A structurally diverse heterocyclic library by decoration of oxcarbazepine scaffold.Clinical utility of eslicarbazepine: current evidence.Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.New antiepileptic drugs that are second generation to existing antiepileptic drugs.Novel anticonvulsant drugs targeting voltage-dependent ion channels.Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Pharmacotherapy of epilepsy: newly approved and developmental agents.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Effects of various antiepileptics used to alleviate neuropathic pain on compound action potential in frog sciatic nerves: comparison with those of local anesthetics.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine.Eslicarbazepine acetate: a well-kept secret?Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats.Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093.Protective profile of oxcarbazepine against oxygen-glucose deprivation in organotypic hippocampal slice culture could involve PI3K cell signaling pathway.Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.
P2860
Q24621327-5FBCD6F2-10D3-41CA-B795-9500ECB82FD5Q24675330-FA4B6E21-FD8A-4C2D-AA5B-AC8D8E8E2ED8Q26745780-37A51C03-B868-40CF-88E5-A64B9A946ABBQ26783002-0D17D8A5-3AB7-41EA-9642-0D302B5A82BDQ26824512-D6F093D6-0618-475E-92A8-49DBA0EC1250Q30411736-58BFBF5C-9754-421A-8BB3-1C5280CA06F5Q33802172-5752790C-8B65-44DC-BA39-A5D5CC818900Q34329823-B6A3A225-CF52-4352-BC79-9E4443D1F8CAQ34375311-A3F4E306-C330-45DF-96E0-0262E7A62038Q34596785-474BDFF5-FFD1-4528-9419-4DDC9CD53A83Q35033625-E14D1958-8969-4489-832F-11296DAABB3AQ35087964-F98738C3-1F47-4508-AA7E-5255489F2A62Q35161125-02F865DC-E96A-4C73-AAFC-676ECAD55087Q35664957-02DC8DF2-9183-41C5-AD8C-D30E4627B6ACQ36491829-A591EDF8-F4A1-4291-8B54-685143A5DEFEQ36600282-7330C9CB-6480-4C64-A3F7-3774CE37561BQ36947574-24B8BA69-01AC-4E58-AE33-77963996EC3DQ37680030-7C434E78-3536-4F0F-9D2F-7B6B1DF8B118Q37831297-081EDA1A-09F1-4D08-8AA3-4011ACCF2EDCQ37950518-111A5DE1-9CA5-4BAF-BA85-26CEB2BD3872Q37957121-5B5DDB93-897C-48B5-AE2A-5012F6998CCBQ37992162-D06CDE9D-C6D6-428E-AF76-3250F45538A8Q38115721-9EAC6BFF-500E-40E1-82DA-696F297AB2BCQ38223958-4F1352B3-78CA-4F2A-8181-E65C2411D507Q38270290-4C017DBB-46DA-4AE2-8168-C9E839DA422DQ38367761-E7274E90-7A57-45B9-8612-02F63344B73CQ38477044-1BD0F555-B67A-4C61-9A12-5BF8662C9367Q38542064-4CB6586A-CAF1-4D1A-9E4B-1814D704C09AQ38800995-4D619533-CAB9-4628-82C7-F8CF825E6C7FQ40802622-5F4CCA86-FA48-41BA-9DEC-AF25448D034BQ42057556-69335002-52A7-4ABD-ABEF-20FB1AE471CAQ42956261-3F150BFF-6626-40CE-AFE5-66114D606106Q44036387-22745E33-FCD3-466B-8BA6-10AE751FBD99Q44062629-80845C29-1890-460D-9CCE-D63059343AC2Q44553318-3DB54D40-3147-494D-89E7-532AE46EB78FQ45001572-8BFBDE13-1ED2-46B2-BA2C-B83C2B539E4FQ45168033-0F6CBDC0-B7C4-43F5-912A-5DE245A5F29DQ45941023-F3168139-E813-4590-B559-4B23A36C2BAEQ46265751-BF4AA152-D9BE-4DAE-96D0-445BCF4D707BQ46570612-B55E7260-B56B-49A2-A0C3-6F88C0950353
P2860
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@en
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@nl
type
label
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@en
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@nl
prefLabel
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@en
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@nl
P2093
P356
P1476
Anticonvulsant and sodium chan ...... ine-5-carboxamide derivatives.
@en
P2093
Figueiredo AA
Freitas AP
Learmonth DA
P304
P356
10.1021/JM980627G
P407
P577
1999-07-01T00:00:00Z